Abstract CD1d-restricted natural killer T (NKT) cells expressing invariant V 14J 18 T cell receptorchains are abundant in murine liver and are implicated in the control of malignancy, infection and autoimmunity. Invariant NKT cells have potent anti-metastatic eVects in mice and phase I clinical trials involving their homologues in humans are ongoing. However, invariant NKT cells are less abundant in human liver (»0.5% of hepatic T cells) than in murine liver (up to 50%) and it is not known if other hepatic T cells are CD1-restricted. We have examined expression of CD1a, CD1b, CD1c and CD1d mRNA and protein in human liver and evaluated the reactivity of mononuclear cells (MNC) from histologically normal and tumour-bearing human liver specimens against these CD1 isoforms. Messenger RNA for all CD1 isotypes was detectable in all liver samples. CD1c and CD1d were expressed at the protein level by hepatic MNC. CD1d, only, was detectable at the cell surface, but CD1c and CD1d were found at an intracellular location in signiWcant numbers of liver MNC. CD1b was not expressed by MNC from healthy livers but was detectable within MNC in all tumour samples tested. Hepatic T cells exhibited reactivity against C1R cells expressing transfected CD1c and CD1d, but neither CD1a nor CD1b. These cells secreted interferon-(IFN-) but not interleukin-4 (IL-4) upon stimulation. In contrast, similar numbers of peripheral T cells released 13-and 16-fold less IFN-in response to CD1c and CD1d, respectively. CD1c and CD1d expression and T cell reactivity were not altered in tumour-bearing liver specimens compared to histologically normal livers. These data suggest that, in addition to invariant CD1d-restricted NKT cells, autoreactive T cells that recognise CD1c and CD1d and release inXammatory cytokines are abundant in human liver.
Introduction
CD1 molecules comprise a family of glycoproteins that share structural similarities with major histocompatibility complex (MHC) molecules and are specialised in the presentation of lipid antigens to T cells [7, 46] . CD1-restricted T cells play key roles in anti-tumour defence in mice. SpeciWc activation of these cells in vivo results in rapid anti-tumour cytotoxicity and IFNproduction, which can prevent tumour metastasis and promote tumour rejection [14, 28, 41, 50] . CD1-restricted T cells are therefore potential targets for immunotherapy for cancer and phase I trials using CD1-binding glycolipids are ongoing [25, 42] .
Most therapeutic studies involving CD1-restricted T cells have been conWned to the use of a population of CD1d-restricted T cells which expresses natural killer (NK) cell receptors and a T cell receptor (TCR) consisting of an invariant -chain (V 14J 18 in mice and V 24J 18 in humans), which pairs with one of a limited number of -chains [25, 42] . In both species, these "invariant" NKT cells display rapid and potent cytolytic activity and secretion of cytokines (IFN-, IL-2, IL-4 and IL-10), which direct adaptive immune responses [4, 7, 11, 19, 51] . In mice, invariant V 14J 18 + NKT cells generally account for »5% of peripheral blood T cells but they are highly enriched in liver, accounting for 30-50% of all T cells at this location [4, 18] . In contrast, human invariant NKT cells expressing the homologous V 24J 18 TCR -chain are found in signiWcantly lower numbers in human blood (»0.02% of T cells) and liver (»0.5%) [30, 33, 38] and immunotherapy involving invariant NKT cells is less eYcacious than in mice [25, 42] . However, T cells expressing the NK-associated receptors, CD56, CD161, CD94 and killer Ig-like receptors are substantially enriched in adult human liver [16, 43] . Like NKT cells, they display potent cytolytic activity and prompt cytokine secretion but they do not carry invariant TCR chains. It is not known if these NK-like T cells include functional equivalents of murine NKT cells. If they do they could be important potential targets for cancer immunotherapy, based on studies on murine disease models [14, 28, 41, 50] .
While mice encode a single CD1 isoform, CD1d, humans have Wve isoforms, CD1a-e, of which CD1a, CD1b, CD1c and CD1d have been shown to stimulate T cells. CD1a, b and c are expressed by dendritic cells and other antigen-presenting cells and can present a range of lipids (mycolic acids, mycolates esteriWed to simple sugars, phosphatidyl inositol moieties linked to complex glycans, polyisoprenoid lipids and lipopeptides) derived from the cell walls of mycobacteria to T cells [7, 46] . CD1d is expressed by various myeloid, epithelial, parenchymal, and vascular smooth muscle cells in non-lymphoid organs [7, 10, 39, 46] and can present the -anomeric glycolipid, -galactosylceramide ( GC), found in marine sponges [31] and glycosphingolipids from Gram-negative bacteria that do not contain lipopolysaccharide [34] to subsets of T cells. Many CD1-restricted T cells can also be stimulated by exposure to antigen-presenting cells expressing CD1a, CD1b, CD1c or CD1d in the absence of added antigen [19, 45] . This autoreactivity probably results from T cell recognition of endogenous lipid antigens, such as phospholipids, gangliosides, sulphatides and the lysosomal glycosphingolipid, isoglobotrihexosylceramide, which have been shown to bind to human and murine CD1 and activate CD1-restricted T cells [27, 48, 49, 60] .
To ascertain whether the human liver contains functional equivalents of murine invariant CD1d-restricted T cells, we have examined the expression of CD1a, CD1b, CD1c and CD1d mRNA and protein in liver samples taken from healthy donors and patients with hepatic malignancy. Since there are no deWning phenotypic markers for T cells restricted by CD1a, CD1b and CD1c [7, 26, 46, 53] and non-invariant CD1d-restricted T cells which express diverse or TCRs with multiple rearranged junctional sequences have been described [3, 12, 21, 44] , we have evaluated the reactivity of hepatic T cells against a panel of transfectant cells expressing CD1a, CD1b, CD1c and CD1d. Our data indicate that, although invariant NKT cells constitute only a small proportion of human hepatic T cells, CD1c and CD1d are expressed by signiWcant numbers of liver MNC, and autoreactive T cells that recognise CD1c and CD1d and release inXammatory cytokines are abundant in normal and tumour-bearing human liver. We also have found that CD1b is expressed in MNC from tumour-bearing but not normal liver.
Materials and methods

Tissue specimens
Wedge liver biopsies (50-100 mg) were obtained from 14 healthy donor organs at the time of liver transplantation. Liver biochemistry and histology were normal in all cases. Liver tissue was also obtained from 15 patients undergoing resection for hepatic metastases of colonic origin. Wedge biopsies from tumour-bearing tissue were taken approximately 10 cm from the tumour margin and appeared histologically normal. All organ donors and patients were negative for hepatitis A, B, C, and E viruses. Blood samples were obtained from seven healthy donors. Ethical approval for this study was obtained from the Research and Ethics Committee at St. Vincent's University Hospital, Dublin, Ireland.
Preparation of peripheral blood and liver MNC Mononuclear cells were prepared from anti-coagulated whole blood by Lymphoprep (Nycomed, Oslo, Norway) density gradient centrifugation. Single liver cell suspensions, which contain MNC and residual parenchymal cells, were prepared as previously described [43] . CD3 + cells were isolated from fresh hepatic and peripheral MNC preparations by positive selection using monoclonal antibody (mAb)-coated magnetic beads (Miltenyi Biotec, Bergisch Gladbach, Germany). The purity of isolated fractions was assessed by Xow cytometry and only preparations with purities of 95% or greater were used for functional studies.
Analysis of CD1 mRNA RNA was isolated from snap frozen liver specimens using the Rneasy Mini Kit (Qiagen, Crawley, UK) and reverse transcribed into cDNA using Superscript II (Promega, Madison, WI). Polymerase chain reaction (PCR) ampliWcation of CD1a, CD1b, CD1c and CD1d was carried out in separate 25 l reactions containing 1 l cDNA with the following oligonucleotide primer pairs (forward and reverse) [29, 54] : CD1a, ATGCTGTTTTTGCTACTTCCATTGTTA and CGTGGGCAGGTGTCACTGAGAAG, CD1b, ATGCTGCTGCTGCCATTTCAACTGT TA and GGGCAGGTTTCATAGAGGAGAAT TC, CD1c, ATGCTGTTTCTGCAGTTTCTGCTGCT A and CTGTTTCTGTGACGCCTTCATACTG, CD1d, GCTCCACCAGGACAAGTGGACGAG and GGAGGTAAAGCCCACAATGAGGAG.
These primers produced products of 530, 528, 529 and 535 bp, respectively. Thermocycling conditions consisted of an initial incubation at 94°C for 10 min to activate the polymerase enzyme (AmpliTaq Gold, Gibco BRL Life Technologies, Paisley, UK) followed by 30 cycles consisting of 1 min at 94°C, 2 min at 60°C, and 2 min at 72°C. As a control, PCR was performed on all samples using primers speciWc for the housekeeping gene glyceraldehyde phosphate dehydrogenase (GAPDH), GCCTCAAGATCATCAGCAA and CCAGCGTCAAAGGTGGAG.
Antibodies and Xow cytometry
The expression of CD1 protein by liver cells in single cell suspensions was determined by Xow cytometry using the unconjugated mAbs, 10H3.9.3 (CD1a), BCD1b3 (CD1b), F10/21A3 (CD1c) and CD1d51 (CD1d), which we have previously generated [20, 26] . BrieXy, 10 5 cells were incubated with 0.2 g antibody for 20 min at 4°C and washed twice in PBA buVer (PBS containing 1% bovine serum albumin and 0.02% sodium azide). The cells were then incubated for 20 min at 4°C with 5 l of a 1/5 dilution of rabbit antimouse immunoglobulin conjugated to Xuorescein isothiocyanate (Dako, Cambridge, UK), washed as before, and incubated for 15 min at 4°C with 50 l of a 1/25 dilution of Wltered normal mouse serum (Vector Laboratories, Peterborough, UK). Cells were washed twice in PBA buVer and analysed immediately on a FACScan Xow cytometer (Becton Dickinson, Oxford, UK). The expression of CD1 by lymphocytes and nonlymphocytes within MNC was assessed by electronic gating of the lymphocytes which display lower forward and side scatter. C1R cell lines transfected with the individual CD1 isoforms [19] were used as positive controls for mAb staining. Intracellular CD1 was detected by Wxing cells with 4% paraformaldehyde and permeabilising them with 0.2% saponin (Sigma-Aldrich, Dublin, Ireland) before adding the anti-CD1 mAbs [16] .
Assessment of hepatic T cell reactivity against CD1 in vitro
PuriWed hepatic or peripheral CD3 + cells (6 £ 10 RPMI-1640 medium containing 10% foetal calf serum, 20 IU/ml recombinant human IL-2 (National Cancer Institute-Frederick Research Foundation Biological Resources Branch) and 1 ng/ml phorbol myristate acetate (Sigma-Aldrich) in a Wnal volume of 250 l. For CD1 blocking experiments, the C1R-CD1 transfectants were Wrst mixed with 1.0 g/ml of the relevant mAb or isotype matched control antibody before addition of T cells. After 48-72 h supernatants were removed for analysis of IFN-and IL-4 production by enzymelinked immunosorbent assays (ELISA) using mAb pairs obtained from R&D Systems (Abingdon, UK). The invariant NKT cell line, LPK 89 [23] , was used as a positive control for in vitro CD1d-reactivity.
Statistical analyses
Mean Xuorescence intensities and cytokine levels were compared using the unpaired Student's t test and P values of <0.05 were considered signiWcant.
Results
Expression of CD1 mRNA in human liver
PCR ampliWcation of reverse transcribed mRNA was used to analyse the presence of CD1a, CD1b, CD1c and CD1d transcripts in normal (n = 14) and tumourbearing (n = 15) liver samples. Representative results for four normal and three tumour-bearing liver samples are shown in Fig. 1 . CD1a transcripts were found to be variably present in all liver samples examined. CD1b, CD1c and CD1d mRNA were found to be abundant in whole liver samples from both normal and tumour-bearing tissue (Fig. 1) .
Expression of CD1 protein by human liver MNC
The expression of CD1a, CD1b, CD1c and CD1d protein isoforms by freshly isolated hepatic MNC was examined by mAb staining and Xow cytometry. Mocktransfected C1R cells and C1R cells transfected with CD1a, CD1b, CD1c or CD1d were used as positive controls for mAb staining (Fig. 2a) . While CD1a, b and c were not expressed at the cell surface of MNC from Wve normal liver samples tested, CD1d was weakly expressed (Fig. 2b, c) . No induction or reduction of cell surface expression of any of the CD1 isoforms was detected in Wve samples of tumour-bearing liver cells (Fig. 2c) .
To detect whether CD1 isoforms are expressed intracellularly, cell suspensions from Wve normal livers were permeabilised with saponin before mAb staining and analysed by Xow cytometry (Fig. 2b) . In all samples from healthy livers CD1a and CD1b expression was undetectable following permeabilisation, but signiWcant CD1c and CD1d staining was seen (Fig. 2d) . Separate analysis of the lymphocyte and non-lymphocytes within the liver cell suspensions by electronic gating indicated that both fractions stained positive for CD1c and CD1d (data not shown). Analysis of MNC from Wve tumour-bearing livers showed low but signiWcantly increased intracellular expression of CD1b (P = 0.002) and slightly elevated cell-surface and intracellular expression of CD1d. The changes in CD1d expression were not signiWcant (Fig. 2c, d ).
Hepatic T cell responses to CD1 isoforms
Since CD1 isoforms are expressed in human liver, we next determined whether CD1-reactive T cells were detectable in liver. IFN-and IL-4 secretion by CD3 + cells puriWed from Wve normal donor livers in response to mock-transfected C1R cells or C1R cells transfected with CD1a, CD1b, CD1c or CD1d was measured by ELISA. The levels of cell-surface CD1 expression by the C1R cells used as stimulators were shown by Xow cytometry to be comparable for all CD1 isoforms (Fig. 2a) . Figure 3a shows that minimal responses, comparable to alloresponses, were obtained using the CD1a and CD1b transfectants as stimulators in IFNand IL-4 assays. In contrast, hepatic CD3 + cells from normal liver responded to CD1c and CD1d by releasing IFN-(means 2.37 ng/ml for CD1c and 4.76 ng/ml for CD1d). In all Wve normal samples tested, the CD1d-speciWc IFN-response was comparable to the response to mitogen stimulation of the same cells (3.94 ng/ml) and CD1d stimulation of the human blood-derived invariant NKT cell line, LPK.89. These IFN-levels are signiWcantly higher than those obtained when similar numbers of peripheral blood CD3 + cells were similarly stimulated. Means of 0.17, 0.13, 0.18 and 0.3 ng/ml IFN-(n = 3 samples) were released by peripheral blood T cells in response to C1R cells expressing transfected CD1a, CD1b, CD1c and CD1d, respectively (Fig. 3a, upper central panel) .
No IL-4 was released by hepatic CD3 + cells stimulated with any of the CD1 isoforms. This contrasts with our observations of IL-4 production (mean 121 pg/ml) by hepatic CD3 + cells in response to phytohaemagglutinin stimulation, and by the invariant NKT cell line, LPK.89 (436 pg/ml), in response to CD1d. IL-4 release by CD3
+ PBMC in response to CD1 was not investigated, but undetectable levels of another Th2 cytokine, IL-13, were released peripheral T cells in response to each CD1 isoform (data not shown).
Conformational CD1-speciWc and control mAb blocking experiments were used to determine the speciWcity of the interaction between hepatic CD3 + cells and CD1c and CD1d and to test whether responses were speciWc for intact CD1 rather than CD1 peptides presented indirectly by MHC molecules (Fig. 3b) . Incubation of the transfectants with 0.2 g/ml of anti-CD1c (F10/21A3) or anti-CD1d (CD1d51) mAbs prior to addition of T cells almost completely blocked CD1-induced IFN-production by hepatic CD3 + cells. Therefore, the T cell reactivity against C1R cells expressing CD1c or CD1d is CD1-speciWc and not a result of recognition of the peptide fragments derived from these molecules presented by MHC molecules.
CD1-reactive T cells in tumour-bearing liver IFN-and IL-4 secretion by CD3
+ cells puriWed from Wve tumour-bearing liver specimens in response to mock-transfected C1R cells and C1R cells transfected with CD1a, CD1b, CD1c and CD1d was also measured by ELISA. Figure 4 illustrates that, like normal liver, tumour-bearing liver also contains IFN--producing T cells that are reactive against CD1c and CD1d, but neither CD1a nor CD1b. The levels of IFN-produced by hepatic T cells in response to CD1c were similar in tumour-bearing (means 2.9 ng/ml, range 1.28-5.64 ng/ ml) and normal (2.37 ng/ml, range 1.07-4.13 ng/ml) livers. IFN-production by hepatic T cells in response to CD1d stimulation appeared to be slightly lower using cells derived from tumour-bearing tissue (3.2 ng/ml, range 1.11-8.64) compared with normal hepatic T cells (4.8 ng/ml, range 3.04-8.21 ng/ml), but this diVerence was not signiWcant (P > 0.05). As with normal hepatic CD3 + cells, T cells derived from tumour-bearing livers did not produce measurable IL-4 in response to CD1 stimulation but were capable of comparable IL-4 secretion upon mitogenic stimulation (Fig. 4) .
Discussion
Murine liver contains large numbers of CD1d-restricted invariant NKT cells, with up to 50% of intrahepatic [4, 11, 19, 51] . They can play key roles in immune defence against viruses, bacteria, fungi, parasites and tumours and the prevention of autoimmune disease in various mouse models [7, 28] . NKT cells are therefore under scrutiny as potential targets for immunotherapy for cancer, and multiple clinical trials using GC are under way [25, 42] . In contrast to murine NKT cells, the roles of CD1d-restricted T cells in hepatic immunoregulation and anti-tumour immunity in the human are less clear. Humans have invariant CD1d-restricted NKT cells expressing V 24J 18 TCR -chains, with similar antigen speciWcities and functional activities to murine invariant NKT cells [19] , but which are found in signiWcantly lower numbers in liver (»0.5% of T cells) and blood (»0.02%) compared to their murine counterparts [30, 33, 38] . However, the human liver contains large numbers of T cells with diverse TCRs that express NK cell receptors and display NK-like functional activities [16, 43] . It is possible that hepatic T cells include cells that use non-invariant TCRs to recognise CD1d or the other CD1 isotypes, CD1a-c, which are not found in mice. We have addressed this hypothesis by examining CD1 isotype expression and T cell reactivity to CD1a, CD1b, CD1c and CD1d in healthy and tumour-bearing human livers.
We report that CD1a, CD1b, CD1c and CD1d mRNA were detectable in all adult human liver specimens tested. CD1a and CD1b proteins were not detected at the cell surface or within hepatic MNC from Wve normal livers tested. The Wnding of CD1a and CD1b mRNA but not protein expression suggests that these CD1 isoforms may be expressed by other liver cells. CD1b was expressed intracellularly in Wve of Wve tumour-bearing livers, suggesting that CD1b-restricted T cells may play a role in immunity against tumours. CD1c and CD1d were expressed at very low levels at the cell surface, but were found at an intracellular location in signiWcant numbers of liver MNC from all samples tested, including lymphocytes and non-lymphocytes. Previous work has shown that CD1d is most prominently expressed by intestinal epithelial cells [2, 6] , thymocytes and haematopoietic-derived cells [9, 20] but it has also been reported to be expressed inside hepatocytes in mice [6, 39] and by hepatocytes, cholangiocytes and hepatic MNC in humans with inXammatory diseases of the liver [1, 10, 17, 36, 57] . While CD1d expression does not appear to be induced by individual cytokines or growth factors [52] , the intracellular location of CD1d in normal human liver, found in the present study, suggests that MNC surface expression of CD1d may be rapidly induced by translocation to the cell surface. Future studies are required to determine what signals may mediate this process. We have also detected intracellular, but not cell surface, expression of CD1c by liver MNC, suggesting that this CD1 isoform may also be similarly translocated to the cell surface in response to as yet unknown signals. CD1c is known to be expressed by dendritic cells and B cells [7, 46] , which are abundant in liver.
In addition to our Wnding that CD1c and CD1d are the only CD1 isoforms that show signiWcant expression in human liver MNC, we found that hepatic T cell reactivity against CD1, expressed by C1R cells, was limited to CD1c and CD1d. Stimulation of T cells from a total of ten liver samples with C1R cells expressing CD1c or CD1d resulted in means of 13-fold and 16-fold more IFN-release, respectively, than for stimulation of similar numbers of peripheral blood T cells. Little or no IFN-was released by hepatic T cells in response to CD1a and CD1b. Although it is possible that the transfected C1R cells used in the present study have altered antigen-presenting properties compared to natural antigen-presenting cells, our results suggest that hepatic T cell recognition of CD1 is limited to CD1c and CD1d. CD1d-reactivity of human hepatic T cells from patients with chronic hepatitis C virus infection has also been demonstrated [1, 17, 21] . This reactivity is presumably mediated, in part, by invariant V 24V 11 + NKT cells [30, 33, 38] but invariant NKT cells were found to account for only 0.5% of hepatic T cells [33] . Their low numbers in human liver despite strong CD1d reactivity suggests that other non-invariant CD1d-restricted T cells may predominate. CD1d-restricted NKT cells with diverse TCRs have been described in mice and humans [3, 21, 22, 44] and it is thought that invariant and non-invariant NKT cells sample antigens in diVerent endosomal compartments [12] . Future work is required to determine which T cell subpopulations recognise CD1d; however, previous studies have shown that the human liver harbours several subsets of T cells that, like invariant NKT cells, express NK receptors and mediate NK-like cytotoxicity [16, 32, 33, 43] . Recognition of GC is primarily, although not exclusively, restricted to invariant NKT cells [5, 24, 30] ; therefore, therapies based on GC would be less eYcacious in humans compared to mouse models.
Murine and human invariant NKT cells are notable for their ability to rapidly secrete IFN-and IL-4 upon stimulation with CD1d [4, 11, 19, 51] . The production of these cytokines, which have opposing eVects of Th cell diVerentiation, implicates invariant NKT cells as drivers and regulators of adaptive immune responses. However, we have found that human hepatic T cells speciWcally release IFN-only in response to CD1d-expressing C1R cells. The lack of IL-4 production in this in vitro system is consistent with previous Wndings on human hepatic CD1d-reactive and V 24V 11 + T cells [21, 33] but contrasts with those on CD1d-reactive T cells from human blood [19] and bone marrow [22] . These diVerences suggest that CD1d-reactive T cells may have diVerent immunoregulatory roles in diVerent tissues.
Our observation that human hepatic T cells exhibit signiWcant reactivity against CD1c indicates the presence of a second lineage of potential lipid-recognizing T cells in the human liver. These cells also released IFN-, but not IL-4, in response to stimulation. In the absence of identiWable markers of CD1c-restricted cells, we do not know which T cell populations recognise CD1c, but subpopulations of T cells, most notably V 1 + T cells, are known to be CD1c-restricted [37, 45, 53] . We have reported [32] that human liver is a rich source of T cells, which comprise »7% of hepatic T cells with signiWcant numbers expressing V 1, V 2 and V 3 TCR chains. It is possible that these cells contribute to the CD1c-reactivity. However, not all CD1c-reactive T cells are T cells and several distinct populations of T cells can also recognise CD1c [40, 47] ; therefore, it is likely that the repertoire of hepatic CD1c-reactive T cells is heterogeneous. CD1d-restricted NKT cells play key roles in antitumour defence in mice. Injection of mice with either IL-12 or GC results in tumour rejection by a mechanism that is dependent upon IFN-production and/ or anti-tumour cytotoxicity by NKT cells [41, 50] . Furthermore, mice deWcient in CD1d or NKT cells fail to mediate IL-12-induced rejection of tumours [14] . Numerical and functional deWciencies of NKT cells have been reported in humans with tumours [15, 33, 55, 59] ; therefore, we compared CD1 expression and T cell reactivity against CD1 in liver samples from normal donors and uninvolved liver tissue from patients with metastatic liver disease. We found no signiWcant diVerences in CD1a, CD1c or CD1d mRNA or protein expression and no diVerences in hepatic T cell reactivity against these molecules in the two groups. We found a signiWcant upregulation of intracellular CD1b expression by MNC from tumour-bearing livers compared with healthy livers. We observed a non-signiWcant trend towards less CD1d-and more CD1c-reactivity in tumour-bearing livers compared with normal controls, which mirrors reductions of V 24 + V 11 + NKT cells and expansions of V 1 + T cells which we have seen in patients with hepatic malignancy [32, 33] .
Our data provide evidence that the adult human liver is a site of accumulation of autoreactive T cells that respond to CD1c or CD1d by releasing IFN-. T cells that recognise CD1c and CD1d have been shown to play immunostimulatory roles at early stages of immune responses by responding to self-lipids presented by immature dendritic cells. Upon exposure to microbial products, such as lipopolysaccharide, dendritic cells secrete proinXammatory cytokines (IL-12) that amplify weak responses of invariant NKT cells to CD1d-presented self-antigens [8] . Thus NKT cells can become activated in many diVerent microbial infections, resulting in the release of chemokines and cytokines that promote recruitment and activation of macrophages, NK cells, T cells and B cells. CD1a-drestricted T cells can also reciprocally induce maturation of dendritic cells and their release of IL-12 [35, 37, 56, 58] . The liver is notable for its ability to induce immunological tolerance to dietary antigens entering from the hepatic portal vein [13] despite having multiple lymphocyte populations that display potent Th1 activities ex vivo [16, 43] . Autoreactive CD1-restricted T cells could provide mechanisms whereby active immunity can be rapidly induced within this tolerogenic environment, by maintaining a low level of autoreactivity that can be upregulated in response to pathogens.
